BACKGROUND: Two-drug regimens are increasingly used in clinical practice as switch strategies. We compared the efficacy and safety of two dolutegravir-based dual therapies (DT): dolutegravir plus lamivudine (3TC group) versus DTG plus rilpivirine (RPV group). METHODS: In a multicenter cohort of virologically suppressed (HIV-RNA <50 cp/ml) HIV+ pts switching to DTG+3TC or DTG+RPV we analyzed the incidence of virological failures (VF) and treatment discontinuations (TD), as well as their predictors. RESULTS: We analyzed 416 pts, 229 in the 3TC group and 187 in the RPV group. The 3TC group, during 344.4 person-years of follow-up (PYFU), had 10 VF without the emergence of resistance mutations, while 30 pts discontinued the regimen. In the RPV group, during 371.0 PYFU, there were 5 VF (one developed NNRTI-mutations Y181C and E138Q) and 13 TD. The estimated probability of remaining free from VF at 48 weeks showed no significant difference between groups (log-rank 0.172). We found a higher risk of VF in patients with peak VL>500000cp/ml in both treatment groups (log-rank p=0.004 in each group). The estimated probability of remaining in the study regimen at week 48 was 89.0% with DTG+3TC and 96.1% with DTG+RPV (log-rank 0.015). After adjusting for potential confounders, treatment group was not associated to TD. A significant decrease in total cholesterol was observed at week 48 in both groups while renal function remained unchanged. CONCLUSIONS: DTG+RPV and DTG+3TC were compared in populations with different characteristics in clinical practice: both regimens showed good effectiveness and improved lipid profile.

Ciccullo, A., Baldin, G., Capetti, A., Rusconi, S., Sterrantino, G., D'Ettorre, G., Colafigli, M., Modica, S., Lagi, F., Giacomelli, A., Cossu, M. V., Restelli, S., De Luca, A., Di Giambenedetto, S., A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients, <<ANTIVIRAL THERAPY>>, 2018; (n/a): N/A-N/A. [doi:10.3851/IMP3270] [http://hdl.handle.net/10807/127174]

A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients

Ciccullo, Arturo;Baldin, Gianmaria;Colafigli, Manuela;De Luca, Andrea;Di Giambenedetto, Simona
Ultimo
2018

Abstract

BACKGROUND: Two-drug regimens are increasingly used in clinical practice as switch strategies. We compared the efficacy and safety of two dolutegravir-based dual therapies (DT): dolutegravir plus lamivudine (3TC group) versus DTG plus rilpivirine (RPV group). METHODS: In a multicenter cohort of virologically suppressed (HIV-RNA <50 cp/ml) HIV+ pts switching to DTG+3TC or DTG+RPV we analyzed the incidence of virological failures (VF) and treatment discontinuations (TD), as well as their predictors. RESULTS: We analyzed 416 pts, 229 in the 3TC group and 187 in the RPV group. The 3TC group, during 344.4 person-years of follow-up (PYFU), had 10 VF without the emergence of resistance mutations, while 30 pts discontinued the regimen. In the RPV group, during 371.0 PYFU, there were 5 VF (one developed NNRTI-mutations Y181C and E138Q) and 13 TD. The estimated probability of remaining free from VF at 48 weeks showed no significant difference between groups (log-rank 0.172). We found a higher risk of VF in patients with peak VL>500000cp/ml in both treatment groups (log-rank p=0.004 in each group). The estimated probability of remaining in the study regimen at week 48 was 89.0% with DTG+3TC and 96.1% with DTG+RPV (log-rank 0.015). After adjusting for potential confounders, treatment group was not associated to TD. A significant decrease in total cholesterol was observed at week 48 in both groups while renal function remained unchanged. CONCLUSIONS: DTG+RPV and DTG+3TC were compared in populations with different characteristics in clinical practice: both regimens showed good effectiveness and improved lipid profile.
2018
Inglese
Ciccullo, A., Baldin, G., Capetti, A., Rusconi, S., Sterrantino, G., D'Ettorre, G., Colafigli, M., Modica, S., Lagi, F., Giacomelli, A., Cossu, M. V., Restelli, S., De Luca, A., Di Giambenedetto, S., A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients, <<ANTIVIRAL THERAPY>>, 2018; (n/a): N/A-N/A. [doi:10.3851/IMP3270] [http://hdl.handle.net/10807/127174]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/127174
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 33
social impact